His-tag ELISA for the detection of humoral tumor-specific immunity
Open Access
- 29 May 2008
- journal article
- research article
- Published by Springer Nature in BMC Immunology
- Vol. 9 (1) , 23
Abstract
Background: The application of high throughput molecular techniques such as SEREX are resulting in the identification of a multitude of tumor associated antigens. As newly identified antigens are incorporated into a variety of clinical trials, standardization of immunologic monitoring methods becomes increasingly important. We questioned whether mammalian cell expression of a histadine-linked human protein could be used to produce antigen suitable for detecting tumor-specific humoral immunity and whether such an assay could be amenable to standardization for clinical use. Methods: We designed a his-tagged capture ELISA based on lysate from genetically engineered CHO cells for detection of antibodies to insulin-like growth factor binding protein 2, a novel tumor antigen. We performed technical and preliminary clinical validation studies, including comparison to a standard indirect ELISA based on commercially prepared recombinant antigen. Results: The his-tagged capture ELISA could be standardized. Precision experiments resulted in CVs < 15%. Linearity and calibration experiments demonstrated r2 values of 0.99. In comparison to Western blot analysis, his-tag and indirect ELISA accurately identified 88% and 93% of samples, respectively. Sample concordance between capture and indirect assays was highly significant (p = 0.003). Furthermore, significantly greater levels of IGFBP-2 antibody immunity were found in cancer patients compared to normal controls (p = 0.008). Conclusion: A genetically engineered cell lysate based ELISA can be amenable to standardization and can detect increased levels of antibody immunity to tumor-associated antigen in cancer patients compared to non tumor-bearing healthy controls.Keywords
This publication has 14 references indexed in Scilit:
- Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast CancerCancer Research, 2008
- Cell Aggregation in a Chinese Hamster Ovary Cell Microcarrier Culture Affects the Expression Rate and N-linked Glycosylation of Recombinant Mouse Placental Lactogen-1aAnnals of the New York Academy of Sciences, 2006
- Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunityJournal of Immunological Methods, 2005
- Quality of Recombinant Protein Determines the Amount of Autoreactivity Detected against the Tumor-Associated Epithelial Cell Adhesion Molecule Antigen: Low Frequency of Antibodies against the Natural ProteinThe Journal of Immunology, 2005
- Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim AnalysisCancer Biotherapy and Radiopharmaceuticals, 2004
- CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant proteinJournal of Immunological Methods, 2004
- Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein—Based VaccineJournal of Clinical Oncology, 2004
- Expression patterns of cell cycle and apoptosis‐related genes in a multidrug‐resistant human colon carcinoma cell lineScandinavian Journal of Gastroenterology, 2004
- An ELISA serum assay for autoantibodies to HSP70 in immune-mediated hearing lossJournal of Immunological Methods, 2003
- Detection of Antiendothelial Cell Antibodies by an Enzyme-Linked Immunosorbent Assay Using Antigens from Cell Lysate: Minimal Interference with Antinuclear Antibodies and Rheumatoid FactorsClinical and Vaccine Immunology, 2003